Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Childhood Germ Cell Tumor, Ovarian Cancer, Teratoma
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Childhood Testicular Cancer, National Cancer Institute.
Source updated: October 10, 2024. Captured 2026-09-09.
Treatment of childhood testicular cancer
There are different types of treatment for children and adolescents with testicular cancer. You and your child's cancer care team will work together to decide treatment. Many factors will be considered, such as your child's overall health and whether the cancer is newly diagnosed or has come back.
Your child's treatment plan will include information about the cancer, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child's cancer care team before treatment begins about what to expect. For help every step of the way, see our booklet, Children with Cancer: A Guide for Parents.
Sources: side effects · Children with Cancer: A Guide for Parents
Treatment for non-germ cell testicular cancer in children is usually surgery to remove the tumor. In some cases, the entire testicle with cancer may need to be removed.
If the cancer comes back after treatment, your child's doctor will talk with you about what to expect and possible next steps. There may be treatment options to shrink the cancer or control its growth. If there are no treatment options, your child can receive care to control symptoms from cancer so they can be as comfortable as possible.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Childhood Testicular Cancer, National Cancer Institute.
Source updated: October 10, 2024. Captured 2026-09-09.
Side effects and late effects of treatment
Cancer treatments can cause side effects. Which side effects your child might have depends on the type of treatment they receive, the dose, and how their body reacts. Talk with your child's treatment team about which side effects to look for and ways to manage them.
Sources: dose
To learn more about side effects that begin during treatment for cancer, visit Side Effects.
Sources: Side Effects
Problems from cancer treatment that begin 6 months or later after treatment and continue for months or years are called late effects. Physical problems, such as problems with fertility, are a late effect of treatment.
Sources: late effects · fertility
Some late effects may be treated or controlled. It is important to talk with your child's doctors about the possible late effects caused by some treatments. Learn more about Late Effects of Treatment for Childhood Cancer.
Source: Childhood Testicular Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 5, 2024. Captured 2026-09-09.
The European Cooperative Study Group for Pediatric Rare Tumors within the PARTNER project (Paediatric Rare Tumours Network - European Registry) has published comprehensive recommendations for the diagnosis and treatment of sex cord–stromal tumors in children and adolescents.[1]
Sources: 1
Treatment options for childhood testicular cancer (non–germ cell tumors) include the following:
Surgery.
There are conflicting data about malignant potential in older males. Most case reports suggest that in pediatric patients, these tumors can be treated with surgery alone.[2,3][Level of evidence C1]; [4][Level of evidence C2] It is prudent to check alpha-fetoprotein (AFP) levels before surgery. Elevated AFP levels usually indicate a malignant germ cell tumor. However, AFP levels and decay in levels are often difficult to interpret in infants younger than 1 year.[5]
Sources: 2 · 3 · Level of evidence C1 · 4 · Level of evidence C2 · 5
Evidence (surgery):
In a study of patients prospectively reported to the German Maligne Keimzelltumoren (MAKEI) registry, 42 patients with sex cord–stromal tumors were identified. All tumors were confined to the testes. Patients were treated with surgery alone, according to specific germ cell tumor guidelines.[6][Level of evidence C1]
Sources: 6 · Level of evidence C1
In a study of patients prospectively reported to the German Maligne Keimzelltumoren (MAKEI) registry, 42 patients with sex cord–stromal tumors were identified. All tumors were confined to the testes. Patients were treated with surgery alone, according to specific germ cell tumor guidelines.[6][Level of evidence C1]
There were no tumor recurrences.
A French registry identified 11 boys with localized sex cord–stromal testicular tumors. All 11 boys were treated with surgery alone.[7][Level of evidence C1]
Sources: 7 · Level of evidence C1
A French registry identified 11 boys with localized sex cord–stromal testicular tumors. All 11 boys were treated with surgery alone.[7][Level of evidence C1]
There were no tumor recurrences.
The benign behavior of pediatric non–germ cell testicular tumors has led to reports of testis-sparing surgery.[8-12] In one series of 12 patients with Leydig cell tumors (aged 4.2–14.7 years), 3 were treated with enucleation alone, and 9 were treated with orchiectomy.[13][Level of evidence C1]
Sources: 8 · 12 · 13 · Level of evidence C1
The benign behavior of pediatric non–germ cell testicular tumors has led to reports of testis-sparing surgery.[8-12] In one series of 12 patients with Leydig cell tumors (aged 4.2–14.7 years), 3 were treated with enucleation alone, and 9 were treated with orchiectomy.[13][Level of evidence C1]
All patients were alive at the last follow-up.
Given the rarity of this tumor, the best surgical approach in pediatrics has not yet been defined.
Source: Childhood Testicular Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 5, 2024. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Source: Childhood Testicular Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 5, 2024. Captured 2026-09-09.
Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:
Sources: 1
Primary care physicians.
Pediatric surgeons.
Pathologists.
Pediatric radiation oncologists.
Pediatric medical oncologists and hematologists.
Ophthalmologists.
Rehabilitation specialists.
Pediatric oncology nurses.
Social workers.
Child-life professionals.
Psychologists.
Nutritionists.
For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.
Sources: Supportive and Palliative Care
The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.
Sources: 2 · NCI website
Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3-5] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.
Sources: 3 · 5 · Late Effects of Treatment for Childhood Cancer
Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[6] The U.S. Rare Diseases Act of 2002 defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.
Sources: 6 · Rare Diseases Act of 2002
The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.[7,8] In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:
A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included in the very rare group due to a lack of knowledge and expertise in the management of these tumors.[9]
Sources: 9
The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).[10] These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.[4] Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.
These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.
Information about these tumors may also be found in sources relevant to adults with cancer, such as Testicular Cancer Treatment.
Sources: Testicular Cancer Treatment
Childhood Germ Cell Tumor, Ovarian Cancer, Teratoma
ClinicalTrials.gov recordTesticular Cancer in children and adolescents
Recurrent Childhood Malignant Germ Cell Tumor
Refractory Childhood Malignant Germ Cell Tumor